Prescription stimulant medication misuse: Where are we and where do we go from here?
Prescription stimulants, including methylphenidate (e.g., Ritalin) and amphetamine compounds (e.g., dextroamphetamine; Adderall), have been approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD) and are classified by the United States Drug Enforcement Administration as Schedule II medications because of their high potential for abuse and dependence (Drug Enforcement Administration, U.S. Department of Justice, 2015). Despite the potential health and judicial consequences, misuse of prescription stimulants, typically defined as taking stimulants without a valid prescription, or use of stimulants other than as prescribed, has become a serious problem in the United States and abroad, especially on college campuses. The purpose of the present article is to review historical information concerning prescription stimulants and to summarize the literature with respect to misuse among adults, particularly college students, including risk factors, mediators and moderators, and motivations for prescription stimulant misuse. In addition, evidence is presented concerning the question of whether prescription stimulants truly enhance cognitive functioning in individuals with and without ADHD, and the ethical and professional implications of these findings are explored. Lastly, recommendations for addressing prescription stimulant misuse and suggestions for future research are advanced. (PsycINFO Database Record
Department of Psychology.
Lisa L
LL
Weyandt
Department of Psychology.
Danielle R
DR
Oster
Alpert Medical School of Brown University.
Marisa E
ME
Marraccini
Department of Psychology.
Bergljot Gyda
BG
Gudmundsdottir
Department of Psychology.
Bailey A
BA
Munro
Department of Psychology.
Emma S
ES
Rathkey
Department of Psychology.
Alison
A
McCallum
D000697:Central Nervous System Stimulants; D006801:Humans; D015201:Meta-Analysis as Topic; D063487:Prescription Drug Misuse
D000697:Central Nervous System Stimulants
Psychopharmacology (Berl). 1999 Oct;146(4):482-91
10550499
J Am Coll Health. 2000 Nov;49(3):143-5
11125642
Mayo Clin Proc. 2001 Mar;76(3):323-6
11243281
Rev Panam Salud Publica. 2001 Feb;9(2):114-22
11293829
J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S
11833633
J Am Acad Child Adolesc Psychiatry. 2002 Mar;41(3):253-61
11886019
Nutr Neurosci. 2002 Oct;5(5):311-20
12385593
Behav Pharmacol. 2002 Sep;13(5-6):355-66
12394411
J Stud Alcohol. 2002 Nov;63(6):755-61
12529076
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6186-91
12716966
Addict Behav. 2003 Aug;28(6):1167-73
12834659
J Clin Psychopharmacol. 2004 Feb;24(1):24-9
14709943
JAMA. 2004 Jan 14;291(2):167-70
14722128
Nature. 2004 Jan 22;427(6972):311-2
14737157
Cardiol Rev. 2004 Sep-Oct;12(5):282-3
15316310
Addiction. 2005 Jan;100(1):96-106
15598197
J Am Coll Health. 2005 Jan-Feb;53(4):167-74
15663065
J Am Coll Health. 2005 May-Jun;53(6):253-62
15900989
J Am Coll Health. 2006 Mar-Apr;54(5):261-8
16539218
N Engl J Med. 2006 Apr 6;354(14):1445-8
16549404
Pharmacotherapy. 2006 Oct;26(10):1501-10
16999660
Arch Intern Med. 2006 Sep 25;166(17):1855-62
17000942
Arch Clin Neuropsychol. 2006 Dec;21(8):797-807
17049803
Am J Geriatr Pharmacother. 2006 Dec;4(4):380-94
17296542
Cell Mol Life Sci. 2007 Apr;64(7-8):934-46
17347797
Lancet. 2007 Mar 24;369(9566):1047-53
17382831
Annu Rev Neurosci. 2007;30:475-503
17600524
Hum Psychopharmacol. 2007 Dec;22(8):529-36
17910020
Subst Abuse Treat Prev Policy. 2007 Oct 31;2:32
17974020
Nat Rev Neurosci. 2008 Jan;9(1):58-65
18094706
Nature. 2007 Dec 20;450(7173):1157-9
18097378
J Neural Transm (Vienna). 2008;115(2):357-62
18264813
CNS Drugs. 2008;22(3):213-37
18278977
Am J Addict. 2008 May-Jun;17(3):167-71
18463991
J Am Coll Health. 2008 May-Jun;56(6):601-6
18477513
J Atten Disord. 2009 Nov;13(3):259-70
18664714
J Am Coll Health. 2008 Nov-Dec;57(3):315-24
18980888
J Clin Psychiatry. 2008 Sep;69(9):1437-48
19012813
Nature. 2008 Dec 11;456(7223):702-5
19060880
Psychol Health Med. 2009 Jan;14(1):97-104
19085316
J Atten Disord. 2009 Mar;12(5):449-59
19218542
Pharm World Sci. 2009 Oct;31(5):509-516
19562500
Pediatrics. 2009 Jul;124(1):71-8
19564285
J Atten Disord. 2009 Nov;13(3):234-50
19620623
J Atten Disord. 2009 Nov;13(3):284-96
19767596
J Subst Abuse Treat. 2010 Apr;38(3):292-8
20129754
Neurosci Biobehav Rev. 2010 Jul;34(8):1256-66
20381522
J Drug Issues. 2008 Fall;38(4):1045-1060
20414361
Pharmacol Res. 2010 Sep;62(3):187-206
20416377
J Atten Disord. 2010 Nov;14(3):205-15
20479474
J Atten Disord. 2011 Jul;15(5):347-56
20484709
Kennedy Inst Ethics J. 2010 Jun;20(2):145-60
20653250
BMC Psychiatry. 2010 Sep 03;10:67
20815868
J Drug Educ. 2010;40(2):157-71
21133329
World J Biol Psychiatry. 2012 Jan;13(1):48-59
21155632
Drug Des Devel Ther. 2011 Feb 03;5:71-6
21340040
Postgrad Med. 2011 May;123(3):99-108
21566420
Drug Alcohol Depend. 2011 Nov 1;118(2-3):452-8
21665384
Psychol Bull. 2011 Sep;137(5):717-41
21859174
J Atten Disord. 2013 Feb;17(2):87-97
22142699
J Atten Disord. 2012 Apr;16(3):202-20
22166471
Addiction. 2012 Mar;107(3):467-77
22313101
Am J Psychiatry. 2012 Feb;169(2):160-6
22420039
J Am Coll Health. 2012;60(3):226-34
22420700
Psychol Addict Behav. 2012 Dec;26(4):939-47
22428861
Addict Behav. 2012 Aug;37(8):890-9
22541802
Psychol Addict Behav. 2012 Sep;26(3):678-82
22545584
BMC Cardiovasc Disord. 2012 Jun 09;12:41
22682429
Wien Med Wochenschr. 2012 Jun;162(11-12):262-71
22707077
Neuropharmacology. 2013 Jan;64:496-505
22884611
Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27
22917983
Genes Brain Behav. 2013 Feb;12(1):13-20
23231539
Pharmacotherapy. 2013 Jan;33(1):44-50
23307544
Drug Alcohol Depend. 2013 Sep 1;132(1-2):362-8
23570818
Acad Med. 2013 Jul;88(7):967-71
23702522
Am J Bioeth. 2013;13(7):23-33
23767434
Am J Bioeth. 2013;13(7):39-41
23767438
J Clin Psychiatry. 2013 Jul;74(7):694-702
23945447
BMC Psychiatry. 2013 Sep 27;13:237
24074240
Exp Clin Psychopharmacol. 2013 Oct;21(5):385-407
24099359
PLoS One. 2013 Nov 13;8(11):e77967
24236008
Addict Behav. 2014 May;39(5):987-93
24561016
BMC Med Ethics. 2014 Mar 07;15:23
24606831
Int J Environ Res Public Health. 2014 Mar 12;11(3):3032-45
24625621
Addict Behav. 2014 Jul;39(7):1176-82
24727278
J Atten Disord. 2016 Sep;20(9):741-53
24756173
Addict Behav. 2014 Dec;39(12):1798-803
25123349
Psychol Res Behav Manag. 2014 Sep 09;7:223-49
25228824
Drug Alcohol Depend. 2014 Dec 1;145:106-12
25454408
Clin Child Fam Psychol Rev. 2015 Mar;18(1):50-76
25575768
J Cogn Neurosci. 2015 Jun;27(6):1069-89
25591060
J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14
25692608
Drug Alcohol Depend. 2015 May 1;150:1-13
25724076
Drug Alcohol Depend. 2015 Jul 1;152:224-9
25908322
Int Rev Neurobiol. 2015;120:179-204
26070758
Drug Alcohol Depend. 2015 Aug 1;153:94-103
26116930
Psychopharmacology (Berl). 2016 Jan;233(1):89-97
26429791
Drug Alcohol Depend. 2016 Mar 1;160:157-62
26811120
J Clin Psychiatry. 2016 Mar;77(3):e297-304
26890573
Case Rep Cardiol. 2016;2016:7967851
26998366
Exp Clin Psychopharmacol. 2016 Aug;24(4):269-84
27454675
J Atten Disord. 2016 Dec 1;:1087054716684379
28013572
Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):269-73
6890702
Psychopharmacology (Berl). 1997 May;131(2):196-206
9201809
J Clin Psychiatry. 1998;59 Suppl 7:42-9
9680052